Sharecafe

Immutep updates market on TACTI-004 and pipeline priorities

Marc Voigt discusses next steps, data review and upcoming clinical milestones
Immutep (ASX: IMM) (NASDAQ : IMMP) CEO & Executive Director Marc Voigt discusses the TACTI-004 trial update and outlines the company’s next steps, including a detailed data review and strategic planning. He also highlights ongoing progress across the pipeline, with multiple programs advancing and further clinical milestones expected.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories

Subscribe

get the latest